Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03812562 · ClinicalTrials.gov registry record · Early Phase 1
Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
A Early Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 2
- Enrollment target
NCT03812562 is a Early Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 2 participants.
The verdict
NCT03812562, a Early Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This early phase I trial studies how well nivolumab and yttrium-90 work in treating patients with liver cancer who are undergoing surgical resection. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radioactive drugs, such as yttrium-90, may carry radiation directly to tumor cells and not harm normal cells. Giving nivolumab and yttrium-90 may work better in treating patients with liver cancer.
Interventions
- BIOLOGICAL Nivolumab
- RADIATION Yttrium Y 90 Glass Microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2023-10-19 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03812562
The ClinicalTrials.gov registry entry for NCT03812562 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03812562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03812562 about?
NCT03812562 is a clinical study titled "Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection". This early phase I trial studies how well nivolumab and yttrium-90 work in treating patients with liver cancer who are undergoing surgical resection. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body?s immune system attack the cancer, and may interfere with the ability o...
What is the current status of trial NCT03812562?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 2 participants. The study started on 2019-02-07. Estimated completion is 2023-10-19.
What interventions are being tested in trial NCT03812562?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Yttrium Y 90 Glass Microspheres (RADIATION).
Who is sponsoring clinical trial NCT03812562?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.